Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Blood (2020) 135 (6): 411–428.

https://doi.org/10.1182/blood.2019001262

Published: 2020

Includes: Supplemental data

Journal Articles

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status

Blood (2017) 130 (2): 156–166.

https://doi.org/10.1182/blood-2016-12-758219

Published: 2017

Includes: Supplemental data

Journal Articles

PALB2 Mutational Status in Haematopoeitic Malignancies - a Potential Therapeutic Target?

Ceri Oldreive, PhD BSc, Tatjana Stankovic, MD PhD, Philip J Byrd, PhD, Grant S Stewart, PhD, Anna Smith, Alexander J Taylor, Peggy Fooks, Robert Horsley, James I Last, Dragana Janic, MD PhD, Lidija Dokmanovic, MD PhD, A. Malcolm R Taylor

Blood (2016) 128 (22): 2726.

https://doi.org/10.1182/blood.V128.22.2726.2726

Published: 2016

Journal Articles

Kinetics of CLL Subclonal Architecture: Spontaneous Disease Progression or Treatment-Induced Selection?

Ceri Oldreive, Nick Davies, PhD, Anna Skowronska, PhD, Marwan Kwok, MB ChB, MRCP, Guy Pratt, MDPhD, Paul Moss, Michael John Griffiths, BSc, Samuel Clokie, A. Malcolm R Taylor, Tatjana Stankovic

Blood (2015) 126 (23): 167.

https://doi.org/10.1182/blood.V126.23.167.167

Published: 2015

Journal Articles

Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response

Ceri E Oldreive, PhD, Anna Skowronska, PhD, Angelo Agathanggelou, PhD, Helen M Parry, Sergey Krysov, Graham K Packham, PhD, Rudzki Zbgniew, Guy Pratt, A. Malcolm R Taylor, PhD, Paul Moss, MDPhD, Tatjana Stankovic, MD PhD

Blood (2014) 124 (21): 3284.

https://doi.org/10.1182/blood.V124.21.3284.3284

Published: 2014

Journal Articles

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

Angelo Agathanggelou, PhD, Anastasia Zlatanou, PhD, Ahmed Gulshanara, MSc, Grant Stewart, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD, Guy Pratt, MD, Paul AH Moss, MD PhD, A. Malcolm R Taylor, PhD, Frederic Colland, PhD, Tatjana Stankovic, MD, PhD

Blood (2011) 118 (21): 3865.

https://doi.org/10.1182/blood.V118.21.3865.3865

Published: 2011

Journal Articles

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Anna Skowronska, Gulshanara Ahmed, Ceri E Oldreive, PhD, David Oscier, MD, Anton Parker, Martin J.S. Dyer, MA, DPhil, Estella Matutes, MD, PhD, A. Malcolm R Taylor, PhD, Paul AH Moss, MD PhD, Tatjana Stankovic, MD PhD

Blood (2011) 118 (21): 467.

https://doi.org/10.1182/blood.V118.21.467.467

Published: 2011

Journal Articles

The PARP inhibitor olaparib induces significant killing of ATM -deficient lymphoid tumor cells in vitro and in vivo

Victoria J. Weston, Ceri E. Oldreive, Anna Skowronska, David G. Oscier, Guy Pratt, Martin J. S. Dyer, Graeme Smith, Judy E. Powell, Zbigniew Rudzki, Pamela Kearns, Paul A. H. Moss, A. Malcolm R. Taylor, Tatjana Stankovic

Blood (2010) 116 (22): 4578–4587.

https://doi.org/10.1182/blood-2010-01-265769

Published: 2010

Includes: Supplemental data

Journal Articles

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

David Da Costa, Victoria J Weston, PhD, Stefan Knapp, PhD, A. Malcolm R Taylor, PhD, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 3238.

https://doi.org/10.1182/blood.V116.21.3238.3238

Published: 2010

Journal Articles

ATM Mutant Lymphoid Tumour Cells Exhibit Impaired Activation of the Redox-Sensitive Nrf2-ARE Detoxification Pathway and Are Differentially Sensitive to Nrf2-Activating Compounds

Victoria J Weston, PhD, Angelo Agathanggelou, PhD, Paul AH Moss, MD, PhD, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 49.

https://doi.org/10.1182/blood.V116.21.49.49

Published: 2010

Journal Articles

CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response

Ceri E Oldreive, PhD, Victoria J Weston, PhD, Paul AH Moss, MD, PhD, Guy Pratt, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 2439.

https://doi.org/10.1182/blood.V116.21.2439.2439

Published: 2010

Journal Articles

Large Scale Screening for DNA Damage-Induced Transcription Factors as Potential Targets for Treatment of CLL with p53 Apoptotic Defect.

Victoria Weston, PhD, Paul Moss, MBBS, PhD, FRCP, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD., PhD

Blood (2009) 114 (22): 3439.

https://doi.org/10.1182/blood.V114.22.3439.3439

Published: 2009

Journal Articles

Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells

Amanda Dutton, Ciaran B. Woodman, Marilyn B. Chukwuma, James I. K. Last, Wenbin Wei, Martina Vockerodt, Karl R. N. Baumforth, Joanne R. Flavell, Martin Rowe, A. Malcolm R. Taylor, Lawrence S. Young, Paul G. Murray

Blood (2006) 109 (6): 2597–2603.

https://doi.org/10.1182/blood-2006-05-020545

Published: 2006

Includes: Supplemental data

Journal Articles

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL

Belinda Austen, Judith E. Powell, Azra Alvi, Ian Edwards, Laura Hooper, Jane Starczynski, A. Malcolm R. Taylor, Christopher Fegan, Paul Moss, Tatjana Stankovic

Blood (2005) 106 (9): 3175–3182.

https://doi.org/10.1182/blood-2004-11-4516

Published: 2005

Journal Articles

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

Azra J. Alvi, Belinda Austen, Victoria J. Weston, Christopher Fegan, David MacCallum, Athos Gianella-Borradori, David P. Lane, Mike Hubank, Judith E. Powell, Wenbin Wei, A. Malcolm R. Taylor, Paul A. H. Moss, Tatjana Stankovic

Blood (2005) 105 (11): 4484–4491.

https://doi.org/10.1182/blood-2004-07-2713

Published: 2005

Journal Articles

Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-κB survival pathway signaling

Victoria J. Weston, Belinda Austen, Wenbin Wei, Eliot Marston, Azra Alvi, Sarah Lawson, Philip J. Darbyshire, Mike Griffiths, Frank Hill, Jill R. Mann, Paul A. H. Moss, A. Malcolm R. Taylor, Tatjana Stankovic

Blood (2004) 104 (5): 1465–1473.

https://doi.org/10.1182/blood-2003-11-4039

Published: 2004

Journal Articles

Microarray analysis reveals that TP53 - and ATM -mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses

Tatjana Stankovic, Mike Hubank, Debbie Cronin, Grant S. Stewart, Danielle Fletcher, Colin R. Bignell, Azra J. Alvi, Belinda Austen, Victoria J. Weston, Christopher Fegan, Philip J. Byrd, Paul A. H. Moss, A. Malcolm R. Taylor

Blood (2004) 103 (1): 291–300.

https://doi.org/10.1182/blood-2003-04-1161

Published: 2004

Journal Articles

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

Andrew R. Pettitt, Paul D. Sherrington, Grant Stewart, John C. Cawley, A. Malcolm R. Taylor, Tatjana Stankovic

Blood (2001) 98 (3): 814–822.

https://doi.org/10.1182/blood.V98.3.814

Published: 2001

Journal Articles

Recurrent ATM mutations in T-PLL on diverse haplotypes: no support for their germline origin

Tatjana Stankovic, A. Malcolm R. Taylor, Martin R. Yuille, Igor Vorechovsky

Blood (2001) 97 (5): 1517–1518.

https://doi.org/10.1182/blood.V97.5.1517

Published: 2001

Journal Articles

Clonal Diversity of Ig and T-Cell–Receptor Gene Rearrangements Identifies a Subset of Childhood B-Precursor Acute Lymphoblastic Leukemia With Increased Risk of Relapse

Elaine Green, Carmel M. McConville, Judith E. Powell, Jillian R. Mann, Philip J. Darbyshire, A. Malcolm R. Taylor, Tatjana Stankovic

Blood (1998) 92 (3): 952–958.

https://doi.org/10.1182/blood.V92.3.952

Published: 1998

NARROW

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status

PALB2 Mutational Status in Haematopoeitic Malignancies - a Potential Therapeutic Target?

Kinetics of CLL Subclonal Architecture: Spontaneous Disease Progression or Treatment-Induced Selection?

Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

The PARP inhibitor olaparib induces significant killing of ATM -deficient lymphoid tumor cells in vitro and in vivo

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

ATM Mutant Lymphoid Tumour Cells Exhibit Impaired Activation of the Redox-Sensitive Nrf2-ARE Detoxification Pathway and Are Differentially Sensitive to Nrf2-Activating Compounds

CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response

Large Scale Screening for DNA Damage-Induced Transcription Factors as Potential Targets for Treatment of CLL with p53 Apoptotic Defect.

Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-κB survival pathway signaling

Microarray analysis reveals that TP53 - and ATM -mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

Recurrent ATM mutations in T-PLL on diverse haplotypes: no support for their germline origin

Clonal Diversity of Ig and T-Cell–Receptor Gene Rearrangements Identifies a Subset of Childhood B-Precursor Acute Lymphoblastic Leukemia With Increased Risk of Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only